Background and Objectives：Currently, the drug-eluting stent (DES) has been widely used because of its excellent clinical outcome. We compared the utilization patterns and clinical outcomes between the DES and the bare metal stent (BMS) in the real world. Subjects and Methods：We retrospectively reviewed the stent registry at the Catholic Medical Center between January 2002 and October 2004. There were 1120 patients treated with DES (n=1837) who were compared to 910 patients who received BMS implantation (n=1238). Results：Patients with de novo lesions in the DES group more frequently had multivessel disease and received a greater number of stents than those in BMS group (p<0.001). The mean diameter of inserted stents was smaller in the DES group (p< 0.001). The follow-up rate for clinical and angiographic evaluations at 6 months after stenting was 91% and 65% (n=592) in the BMS group and 90% and 74% (n=829) in the DES group, respectively. The rate of major adverse cardiac events (death, nonfatal myocardial infarction, or target vessel revascularization) at 6 months was 7.3% in the DES group and 17.5% in the BMS group (p<0.001). The rates of target vessel revascularization in the DES group and in the BMS group were 4.2% and 12.9%, respectively (p<0.001). Conclusion：The patients in the DES group had longer length, smaller diameter and higher number of placed stents, compared to the BMS group. The rates of revascularization and major adverse cardiac events in the DES group were lower than those in the BMS group. (Korean Circulation J 2006;36:178-183) KEY WORDS：Stents；Angioplasty；Prognosis.
Introduction
Restenosis is one of the main limitations of coronary stenting, with reported rates as high as 50% in more complex conditions. 1) Recently introduced drug-eluting stents(DES) appear to be a "breakthrough" technology for the prevention of restenosis. Observational studies 2) and randomized controlled clinical trials [3] [4] [5] [6] have shown a substantial reduction in the restenosis rate with DES compared to conventional stents. However, all clinical trials completed to date have included elective patients with relatively straight forward lesions, and with low to moderate risk for restenosis. The effects of DES implantation in complex, unselected patients, in daily practice, remain largely unknown. 7) Notably, restenosis in a small but significant proportion of patients in the SIRIUS trial, as well as other trials, occurred mainly in patients with diabetes, small vessels and long lesions. 4)8) Moreover, restenosis after DES implantation has been recently shown to occur in association with complex procedures. 9) In the present study, we evaluated the impact of DES on the outcomes of patients treated in the "real world", compared to conventional bare metal stent(BMS) implantation.
Subjects and Methods

Study design and patient population
We reviewed patient's angiographic findings and cli-nical data at Catholic Medical Center from January 2002 to October 2004. Almost a consecutive 1,120 patients with de novo lesions(n=1837) were treated with DES and they were compared to 910 patients who received BMS(n=1238) during the period just prior to the DES group.
We reviewed the stent registry at the Catholic Medical Center with the goal of evaluating the safety and efficacy of DES implantation for patients treated in daily routine medical practice. To include a patient population representative of the 'real world', we have used DES treated patients since November of 2003. As the default strategy for every percutaneous coronary intervention, we used the sirolimus-eluting stent(Cypher ® , Johnson & Johnson-Cordis unit, Miami Lakes, FL) and the paclitaxel-eluting stent(Taxus ® , Boston Scientific, Natick, MA).
A total of 1120 patients with de novo lesions were treated with DES and were included in the DES study group. The appropriate DES size, diameter and length, were not always available and accounted for the most common reason for nonutilization of the DES. When DES could not be passed through stenotic lesions, or economic problems were encountered, we substituted the BMS for the DES.
Patients treated with DES were compared to a group of patients treated with BMS for de novo lesions during the preceding months. The present study population was consequently composed of 2,030 patients divided into two sequential cohorts, primarily distinguished by the interventional strategy applied, either BMS or DES.
Procedures and post intervention medications
All interventions were performed according to current standard guidelines and the final interventional strategy was entirely left to the discretion of the operator. Angiographic success was defined if the luminal stenosis of at least one lesion was reduced to less than 30% of the luminal diameter by quantitative coronary angiography(QCA, Pie Medical Imaging, Maastricht, Netherlands) in the presence of Thrombolysis In Myocardial Infarction(TIMI) grade 3 flow. The amount of stenosis of the target lesion, before and after the intervention, was calculated by QCA. Periprocedural antithrombotic medications were used according to the operator's decision; all patients were advised to maintain lifelong aspirin(100 mg/day). A course of at least 1-month ticlopidine treatment(250 mg bid/day) was recommended for patients in the BMS group. For patients treated with DES, clopidogrel(75 mg/day) or ticlopidine(250 mg bid/day) were prescribed for at least 6 months.
End points definitions and clinical follow-up
The primary clinical end point of the study was a composite of major adverse cardiac events(MACE) at 6 months defined as death, nonfatal myocardial infarc-tion, or target vessel revascularization(TVR). A non-Q-wave AMI was defined as troponin I elevation above the upper limit of normal and creatine kinase-MB enzyme elevation ≥3 times the upper limit of the normal. When in addition to enzyme elevation, there were new pathological Q waves observed on the electrocardiogram, the event was defined as a Q-wave AMI. Target lesion revascularization(TLR) was defined as a repeat revascularization with a stenosis ≥50% within the stent or in the 5-mm distal or proximal segments adjacent to the stent; TVR was defined as repeat revascularization within the treated vessel.
Information about the in-hospital outcomes and post discharge outcomes were obtained from medical records. Most patients received noninvasive testing for myocardial ischemia. During follow-up, coronary angiography was performed as per routine follow-up or if clinically indicated by symptoms or documentation of myocardial ischemia. We tried to do angiographic re-study on all patients after 6 months regardless of ischemic symptoms. Clinically driven repeat revascularization was defined as any intervention motivated by a significant luminal stenosis(>50% diameter stenosis) in the presence of anginal symptoms and/or proven myocardial ischemia in the target vessel territory by noninvasive testing.
Statistical analysis
Continuous data were expressed as mean±standard deviation(SD) and were compared by means of the Student unpaired t-test. Categorical variables were presented as counts and percentages and compared by means of the Chi-square test. All statistical tests were 2-tailed. Computation was performed using the SPSS statistical package, version 11.5(SPSS Inc, Chicago, IL).
Results
Patient characteristics
Between January 2002 and October 2004, 910 patients received the DES and 1120 patients received the BMS. Clinical follow up at 6 months was achieved in 92% (n=857) in the DES and in 89% patients(n=997) in BMS group(p=0.12); Angiographic follow-up was performed on 62%(n=564) in the DES group and 47% (n=526) in the BMS groups(p<0.001). With the exception of a significantly higher percentage of hypertension, smoking and multivessel disease in the DES group, the two groups were similar with respect to all other variables examined. The patient characteristics in the study population are presented in Table 1 .
Procedural characteristics
The lesions in the two groups were treated similarly with the use of conventional techniques. We used cypher (n=1003, 81%) and taxus stents(n=235, 19%) in the DES group. Bx velocity(n=409, 33%), Express(n=223, 18%), Tsunami(n=186, 15%), Coroflex(n=99, 8%), S7(n=124, 10%), MAC(n=74, 6%), Multilink(n=111, 9%), and other stents(n=12, 1%) were used in BMS group. Patients treated with DES had a significantly higher number of stents used(2.11±0.76 vs.1.52±0.62 in BMS group)(p<0.001). In addition, the total stented length per patient was longer in the DES group(35.3± 18.3 mm vs. 21.5±13.0 mm in BMS group)(p<0.001). The primary success rate as measured by angiography was similar in both groups( Table 2 ).
The reference diameter was significantly smaller in the DES group(2.91±0.69 mm vs. 3.11±0.78 mm in BMS group). Complex lesions were more frequent in the DES group(p<0.001) and smaller diameters of the stents used were more frequent in the DES group(p<0.001) ( Table 3) .
Clinical outcomes
Follow-up clinical information was obtained from the medical record. The six-month risk for MACE was significantly reduced in the DES group(7.3% vs. 17.5% in the BMS group, p<0.001). The TVR was significantly lower in the DES group than in the BMS group(4.2% vs. 12.9%, p<0.001)( Table 4 ).
Subgroup analysis
Among the 602 patients with diabetes(30 percent of the total study population; 255 patients in the BMS group and 347 patients in the DES group), the rates of 6-months MACEs were higher than those among patients without diabetes in both treatment groups(23.1% vs. 15.5% in BMS groups, 11.1% vs. 5.5% in DES group, respectively p<0.001). Patients with diabetes mellitus (DM) were older(64.4±12.3 years vs. 58.2±8.1 years, p<0.001), and included a higher percentage of males (68% vs. 61%, p=0.027), compared to patients without DM. The reference diameters were 2.84±0.52 mm in the DM patients and 2.89±0.49 mm in the non-DM patients(p=0.021). Lesion lengths were 31.5±18.1 mm in the DM patients and 27.8±17.8 mm in the non-DM patients(p<0.001). The minimal lumen diameters of the DM patients were narrower than those of patient without DM, before(0.58±0.32 mm vs. 0.69±0.37 mm, p<0.001) and after intervention(2.73±0.36 mm vs. 2.82±0.44 mm, p<0.001). Late losses at 6 months were 0.42±0.61 mm in the DM patients and 0.26±0.48 mm in the non-DM patients(p<0.001). Restenosis rates at Table 5 ).
The results of long-stenting were as follows. A total of 173 patients(178 lesions) were implanted with 1 DES or ≥2 DES with overlapping stents in a coronary lesion more than 30 mm in length. Follow up angiograms were done in 57 patients among 173 patients. The total binary restenosis rate was 5.26%(3 of 57 patients). The mean clinical follow-up and angiographic follow-up were, relatively, 6.3±4.1 months and 5.6±2.5 months. Follow-up angiography showed the late lumen losses at 6 months were 0.16±0.18 mm(proximal 5 mm of in-segment), 0.20±0.46 mm(within the stent) and 0.18± 0.34 mm(distal 5 mm of in-segment)( Table 6 ). The rate of MACE in long-stenting at 6 months was 8.7%(15 of 173 patients).
Discussion
DES implantation has been shown to markedly decrease the incidence of restenosis in the context of randomized trials. [3] [4] [5] [6] However, these studies have enrolled patient populations referred for elective intervention without complex lesions. As a consequence, the findings from these studies cannot be directly extrapolated to many patients treated in everyday practice, where complex, nonselected cases are the rule rather than the exception. In the present study, DES with paclitaxel or sirolimus was equivalent to BMS in terms of survival rate. However, DES implantation was associated with a reduction in the rates of repeat revascularization and MACE at 1 year in unselected patients. Our results are supported by trials conducted in Germany and the Netherlands. 10)11) Our study used a strategy that compared DES to conventional approaches that used BMS in the pre-DES era. Although the two study groups were consecutively included over a total period of 3 years, some important differences were noted in the interventional strategy applied. Patients in the DES phase were treated with an aggressive interventional approach, with a significant increase in the number and length of implanted stents and a decrease in the diameter of the stents. Our findings may also reflect an attempt to accomplish more complete lesion coverage and ensure uniform drug delivery over the entire diseased segment; this is important since stent discontinuity and edge injury have been recently shown to be associated with post-DES restenosis. 9) Moreover, the higher degree of complexity of patients treated with DES(e.g., high rates of multivessel disease, type C lesions) may translate into a change in the decision-making process promoted by the availability of DES. Although both study groups differed in some baseline and procedural characteristics, which may somewhat limit an unbiased comparison between them, hypertension, smoking and multivessel disease would traditionally be expected to increase the incidence of late complications in the DES treated patients.
The three principal determinants of restenosis after coronary-stent implantation are DM status, the reference-vessel diameter and the lesion length. 12) In particular, patients with diabetes are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases their likelihood of requiring revascularization. 13)14) The risk of restenosis was increased by approximately 50 percent among diabetic patients who received a BMS as compared with those without diabetes who received such a stent. 15) By contrast, the risk of restenosis was reduced by more than 80 percent among patients with diabetes who received a DES. 16) The subgroup analysis of our DM patients showed that DES markedly reduced the incidence of restenosis when compared to BMS, both in patients without diabetes and in those with diabetes. Recent studies show the same results. 17)18) However, the restenosis rate is still higher in the DM group despite DES. 16) Our results also showed that the restenosis rate is higher in the DM group in the DES era. Revascularization strategies for DM patients with multivessel disease have two options, percutaneous coronary intervention or aortocoronary bypass surgery. Aortocoronary bypass surgery is considered to be the preferred revascularization strategy as reported in the BARI study using a balloon technique. 19) However, recent data using the BMS has demonstrated comparable survival rates between PCI and CABG in the DM groups. [20] [21] [22] Therefore, using DES, for DM patients with multivessel disease, will improve both the survival rate and MACE.
Long stenting using BMS is an independent predictor of restenosis and adverse events. Long stenting is frequently associated with prolonged intracoronary manipulation due to multiple and overlapping stent placement, which may lead to injury to vessel wall integrity. Moreover, the greater metal density may potentially be associated with a higher degree of local vascular injury; these concerns may increase the risk of cardiac events and restenosis. The incidence of late complications has been reported to be directly proportional to the total length of stents implanted. 23)24) Previously, Schalij et al reported a 25% incidence of major adverse events for patients treated with the BMS at a mean stented length of 45 mm. 25) The Additional Value of NIR Stents for the Treatment of Long Coronary Lesions(ADVANCE) Study 26) showed the reported MACE rate was 23%. However, recent studies with DES(Degertekin et al. 23) and Schofer et al. 24) ) showed a reduced restenosis as well as reduced MACEs rate. Our study also revealed the relatively low incidence of MACEs rate(8.9%) with a long length implanted DESs(40±10.1 mm on average).
Overall, the treatment results from DES were significantly better than BMS. However, the presence of diabetes and the treatment of long lesions were shown to independently increase the incidence of complications. These findings highlight the need for further study with a larger group of patients to fully determine the clinical impact of DES in higher-risk patients and in-stent restenosis [27] [28] [29] in these patients.
Conclusion
This study demonstrates that utilization of DES in the "real world" is safe and effective for reducing revascularization and incidence of MACEs at 6 months, compared to BMS implantation.
